INVESTORS & MEDIA
News Release
Regeneron to Participate in Guggenheim Biopharma Strategy Series
A live audio webcast will be available on the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.
About Regeneron
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
Investor Relations
914.847.7786
justin.holko@regeneron.com
View original content:http://www.prnewswire.com/news-releases/regeneron-to-participate-in-guggenheim-biopharma-strategy-series-301317654.html
SOURCE